| |
Early RA (n = 33)
|
Established RA (n = 40)
|
|---|
| |
No progression (SHS <1)
|
Progression (SHS ≥1)
|
P-value (U-test)
|
No progression (SHS <1)
|
Progression (SHS ≥1)
|
P-value (U-test)
|
|---|
|
Patients, n
|
13
|
20
|
–
|
20
|
20
|
–
|
|
DAS28 ESR
|
5.0 (4.4 to 5.7)
|
6.1 (5.3 to 6.5)
|
0.04
|
1.9 (1.4 to 2.3)
|
1.9 (1.6 to 2.7)
|
0.56
|
|
Mean age (SD), yr
|
50.9 (5.2)
|
51.3 (5.0)
|
0.82
|
50.3 (10.6)
|
51.5 (13.9)
|
0.77
|
|
Sex, n (% female)
|
10 (77%)
|
13 (65%)
|
–
|
14 (70%)
|
16 (80%)
|
–
|
|
Baseline SHS
|
0 (0 to 0)
|
2.5 (1.0 to 6.8)
|
0.0002
|
1.0 (0 to 16)
|
38.7 (23.2 to 56.8)
|
<0.0001
|
|
CRP, mg/L
|
12.0 (6.0 to 22.5)
|
12.5 (6.5 to 24.5)
|
0.82
|
3.0 (2.0 to 6.0)
|
8.0 (5.3 to 22.0)
|
0.001
|
|
RF, IU/ml
|
0 (0 to 160.0)
|
160.0 (40.0 to 320.0)
|
0.035
|
48.0 (2.0 to 68.0)
|
55.0 (19.5 to 223.8)
|
0.13
|
|
ACPA, U/ml
|
12 (6.5 to 96.0)
|
101.0 (14.3 to 194.3)
|
0.18
|
59.5 (20.3 to 365.9)
|
75.1 (20.3 to 440.3)
|
0.77
|
|
Mean 14-3-3η (SD), ng/ml
|
1.30 (3.51)
|
6.13 (8.33)
|
0.03
|
3.76 (6.92)
|
4.37 (8.02)
|
0.79
|
|
Median 14-3-3η (IQR), ng/ml
|
0.09 (0.06 to 12.59)
|
2.68 (0.12 to 15.94)
|
0.006
|
0.28 (0 to 4.54)
|
1.11 (0.10 to 2.89)
|
0.16
|
- aACPA, Anticitrullinated protein antibody; SHS, Sharp/van der Heijde score; CRP, C-reactive protein; DAS28 ESR, Disease Activity Score in 28 joints with erythrocyte sedimentation rate; RA, Rheumatoid arthritis; RF, Rheumatoid factor. P-values were calculated using the Mann–Whitney U test.
